#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Demyelination Frostbite Immune-mediated myasthenia gravis Chronic inflammatory demyelinating polyradiculoneuropathy Hydrocephalus Chronic hepatitis B Haemophilia Breast cancer metastatic Cardiac arrest Malignant fibrous histiocytoma Primary adrenal insufficiency Malformation venous Cholangiocarcinoma Plasma cell myeloma recurrent Cervix carcinoma More trials…

    Learn about Rare Diseases

    Antithrombin III deficiency – Trials in Disease Mastocytosis – Basic Information VEXAS syndrome – Life with Disease Myelodysplastic syndrome Biotinidase deficiency – Diagnostics Indolent systemic mastocytosis – Diagnostics Lymphatic malformation – Trials in Disease IgA nephropathy – Diagnostics Mucopolysaccharidosis III – Life with Disease Rhabdomyosarcoma – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    CYCLIZINE HYDROCHLORIDE Fludrocortisone Acetate Rosuvastatin Zinc Busulfan LINAPRAZAN GLURATE Efinopegdutide Sertraline Hydrochloride Anhydrous Benzoyl Peroxide Treprostinil Cetirizine Dihydrochloride Streptococcus Pneumoniae ICEF15 Losartan RP2 Cx-044933 Olea Europaea Pollen Extract Hdp-101 Pervi-Fus Denosumab Messenger Rna Encoding Cas9 More therapies…

    Learn about Your Condition

    Endometrial cancer stage II Vulval cancer recurrent Rhabdoid tumour Tertiary adrenal insufficiency Procedural pain Renal transplant Obstructive airways disorder Biopsy heart Primary adrenal insufficiency Cerebrovascular accident Bronchopulmonary dysplasia Laryngeal cancer stage III Hypophosphatasia Neurofibromatosis Endocarditis enterococcal More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Sanatorium profesora Arenbergera

Sanatorium profesora Arenbergera

BOLZANOVA 7, Prague, 110 00, Czechia

Want to learn more about this study or check if you can participate? Contact us.

  • A study to evaluate the effectiveness and safety of BFB759 in adults with moderate to severe hidradenitis suppurativa

    Recruiting

    2 1
    Bulgaria Czechia Germany Poland Spain

  • A Study of Brivekimig Compared to Placebo in Patients with Moderate to Severe Hidradenitis Suppurativa

    Recruiting

    2 1
    Investigated Diseases:
    • Hidradenitis
    Czechia France Germany Greece Hungary Italy +3

  • Long-term safety and effectiveness study of APG777 injection in patients with moderate-to-severe atopic dermatitis who previously received APG777 treatment

    Recruiting

    2 1
    Investigated Drugs:
    • Apg777
    Czechia France Germany Hungary Poland Spain

  • Study on the Safety and Effectiveness of EIK1001 and Pembrolizumab for Patients with Advanced Melanoma

    Recruiting

    4 1 1
    Investigated Drugs:
    • Resiquimod Sulfate
    Austria Belgium Bulgaria Czechia Denmark Finland +9

  • Study on Long-Term Safety and Efficacy of Amlitelimab for Patients with Moderate to Severe Atopic Dermatitis from Previous Trials

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Amlitelimab
    Bulgaria Czechia Denmark France Germany Greece +7

  • Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

    Recruiting

    3 1 1
    Investigated Drugs:
    • 4-[3-(Cyanomethyl)-3-(3′,5′-Dimethyl-1H,1’H-[4,4′-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
    • Povorcitinib
    Austria Belgium Bulgaria Czechia Denmark France +7

  • Long-term safety and effectiveness study of ritlecitinib in children with severe alopecia areata who completed previous trials B7981027 or B7981031

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Alopecia areata
    Czechia France Italy Poland Spain

  • Study to evaluate ATI-045 injection compared to placebo in adults with moderate to severe atopic dermatitis

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • HUMANISED IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST THYMIC STROMAL LYMPHOPOIETIN
    Czechia Germany Poland

  • Study on the Effectiveness and Safety of ANB032, Hydrocortisone, and Alclometasone Dipropionate for Patients with Moderate to Severe Atopic Dermatitis

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Alclometasone Dipropionate
    • Anb032
    • Hydrocortisone
    Czechia Poland

  • A study testing TRIV-509 compared to placebo in adults with moderate to severe atopic dermatitis

    Not recruiting

    2 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • HUMAN IGG1 BISPECIFIC MONOCLONAL ANTIBODY AGAINST KALLIKREIN-5 AND KALLIKREIN-7
    Bulgaria Czechia Hungary Poland
1 2 3
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!